Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4879430 Target Snapshot

Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 · SINGLE PROTEIN · Homo sapiens

8Compounds
5Assays
0Approved Drugs
10.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P0C870. Use UniProt P0C870 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P0C870 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 as ChEMBL target CHEMBL4879430, mapped to UniProt P0C870. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4879430
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P0C870
Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 is the right protein anchor across sources, using UniProt P0C870 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBifunctional peptidase and (3S)-lysyl hydroxylase JMJD7
UniProt AccessionP0C870
Component TypeProtein
Sequence Length316 aa

Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7, mapped to UniProt P0C870. Sequence length is 316 aa.

Mapped IDP0C870
Review nameBifunctional peptidase and (3S)-lysyl hydroxylase JMJD7
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC509.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4846929 5.93 Kd 1180.0 Preclinical
CHEMBL4846929 5.42 IC50 3800.0 Preclinical
CHEMBL197194 5.14 IC50 7160.0 Clinical
CHEMBL1498999 4.96 IC50 10970.0 Preclinical
CHEMBL4862698 4.58 IC50 26180.0 Preclinical
CHEMBL1688558 4.5 IC50 31640.0 Preclinical
CHEMBL1081780 4.48 IC50 33160.0 Preclinical
CHEMBL3982723 4.3 IC50 50080.0 Clinical
Distribution

pChEMBL Value Distribution

3
5.0
1
5.5
0
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

5
Total Assays
7
Tested Compounds
1
Assay Types
Binding — 5 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 7 4.9
single protein format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine